Bayer Wins Specialty CV Deal

Bayer will pay $50 million up front and up to $335 million in development and commercialization milestones for ex-US rights to Nuvelo's clot-buster alfimeprase, which complements the German group's specialist cardiovascular portfolio.

Nuvelo Inc. wasn't short of suitors for its clot-buster alfimeprase, in Phase III trials for acute peripheral arterial occlusion (PAO) and venous catheter occlusion (CO), when it first starting seeking partners for the drug last year. Phase III assets are rare as it is; even rarer are those with strong data and clear advantages over existing treatments. That mid-sized German group Bayer AG won the booty may seem surprising; less so, however, considering Bayer's cardiology heritage and pipeline--and its willingness to accept ex-US rights only.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo